Novo Nordisk partners with international scientific community for Victoza cardiovascular outcomes trial

7 May 2010

Danish insulin giant Novo Nordisk yesterday announced details of its cardiovascular outcomes trial for the type 2 diabetes agent Victoza (liraglutide [rDNA origin] injection), which is set to start in the fall of 2010.

The drug, which is still being rolled out in European markets and was launched in the USA earlier this year just weeks after gaining regulatory approval (The Pharma Letter February 17), is expected to generate sales of some $1 billion by 2015, the company believes.

The trial named LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) aims to assess and confirm the cardiovascular safety of the company's new once-daily human GLP-1 analog Victoza. The trial satisfies the new Food and Drug Administration guideline for type 2 diabetes treatments, Novo Nordisk noted.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK